- Home
- FITB vs WAT Comparison
FITB vs WAT Comparison
Compare FITB & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FITB
- WAT
- Stock Information
- Founded
- FITB 1858
- WAT 1958
- Country
- FITB United States
- WAT United States
- Employees
- FITB N/A
- WAT 7600
- Industry
- FITB Major Banks
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- FITB Finance
- WAT Industrials
- Exchange
- FITB Nasdaq
- WAT Nasdaq
- Market Cap
- FITB 25.6B
- WAT 17.8B
- IPO Year
- FITB N/A
- WAT 1995
- Fundamental
- Price
- FITB $42.84
- WAT $302.95
- Analyst Decision
- FITB Buy
- WAT Hold
- Analyst Count
- FITB 14
- WAT 15
- Target Price
- FITB $47.50
- WAT $377.80
- AVG Volume (30 Days)
- FITB 6.7M
- WAT 1.0M
- Earning Date
- FITB 07-17-2025
- WAT 08-04-2025
- Dividend Yield
- FITB 3.47%
- WAT N/A
- EPS Growth
- FITB 2.27
- WAT 8.23
- EPS
- FITB 3.21
- WAT 11.02
- Revenue
- FITB $7,993,000,000.00
- WAT $2,983,253,000.00
- Revenue This Year
- FITB $15.11
- WAT $6.11
- Revenue Next Year
- FITB $4.81
- WAT $6.44
- P/E Ratio
- FITB $13.30
- WAT $27.52
- Revenue Growth
- FITB N/A
- WAT 2.57
- 52 Week Low
- FITB $32.25
- WAT $279.62
- 52 Week High
- FITB $49.07
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- FITB 58.58
- WAT 39.91
- Support Level
- FITB $41.52
- WAT $279.62
- Resistance Level
- FITB $43.68
- WAT $305.00
- Average True Range (ATR)
- FITB 0.83
- WAT 11.48
- MACD
- FITB -0.22
- WAT -2.00
- Stochastic Oscillator
- FITB 46.81
- WAT 29.02
About FITB Fifth Third Bancorp
Fifth Third Bancorp is a diversified financial-services company headquartered in Cincinnati. The company has over $210 billion in assets and operates numerous full-service banking branches and ATMs throughout Ohio, Kentucky, Indiana, Michigan, Illinois, Florida, Tennessee, West Virginia, Georgia, and North Carolina.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.